- Home
- BLKB vs HCM Comparison
BLKB vs HCM Comparison
Compare BLKB & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLKB | HCM |
|---|---|---|
| Founded | 1981 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1811 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | BLKB | HCM |
|---|---|---|
| Price | $38.37 | $15.18 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 2 | 1 |
| Target Price | ★ $60.00 | $13.75 |
| AVG Volume (30 Days) | ★ 524.7K | 31.3K |
| Earning Date | 04-30-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.32 | N/A |
| EPS | ★ 2.37 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.26 | $20.60 |
| Revenue Next Year | $4.25 | $15.62 |
| P/E Ratio | $15.14 | ★ $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.95 | $13.06 |
| 52 Week High | $74.86 | $19.50 |
Technical Indicators
Market Signals| Indicator | BLKB | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 42.42 | 58.97 |
| Support Level | N/A | $14.69 |
| Resistance Level | $40.60 | $15.54 |
| Average True Range (ATR) | 1.83 | 0.47 |
| MACD | 0.18 | 0.06 |
| Stochastic Oscillator | 65.41 | 74.24 |
Price Performance
Historical ComparisonAbout BLKB Blackbaud Inc.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.